TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04363723

Intervention type: OTHER
Intervention: Pulmonary Rehabilitation
Description: Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.

Intervention type: OTHER
Intervention: Pulmonary Rehabilitation
Description: Patients performed a comprehensive pre-lung transplant inpatient pulmonary rehabilitation program for 4 to 5 weeks duration.
Study: NCT01563952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)
Description: 2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
Study: NCT01208324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pills
Description: There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
Study: NCT03637257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified Guedel airway
Description: Monitoring of breathing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified Guedel airway
Description: Monitoring of breathing
Study: NCT03966209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001(PD-1 inhibitor)
Description: 240mg I.V. Q3W
Study: NCT02501967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMET
Description: The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
Study: NCT00570778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol/glycopyrrolate
Description: Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indacaterol
Description: Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indacaterol
Description: Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
Study: NCT03650413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered based on disease status, as described in the protocol.
Study: NCT03379948

Intervention type: DIAGNOSTIC_TEST
Intervention: blood culture
Description: blood culture to diagnose blood stream infection

Intervention type: DIAGNOSTIC_TEST
Intervention: blood culture
Description: blood culture to diagnose blood stream infection
Study: NCT02014506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40mg/M2 once daily IV on days -7 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg IV on day -3 and -2
Study: NCT01563952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)
Description: 2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)
Description: 2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)
Description: 2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
Study: NCT04060433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Therapy
Description: Swedish version of the evidence based manualized Family Therapy
Study: NCT01300000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Milk
Description: ad lib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational infant formula
Description: ad lib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Milk based standard infant formula
Description: ad lib
Study: NCT00287755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
Study: NCT03662789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Isomaltoside 1000
Description: Intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0,9%
Description: Intravenous infusion
Study: NCT02249351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01679704

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Food products
Study: NCT02587104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EpiFix
Description: Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
Study: NCT00005629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP gene hepatocellular carcinoma vaccine
Description: Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP gene hepatocellular carcinoma vaccine
Description: Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFP gene hepatocellular carcinoma vaccine
Description: Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug
Study: NCT00608803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-201-T and doxorubicin
Description: ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
Study: NCT01994109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYOBLOC
Description: MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MYOBLOC
Description: MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study: NCT04691349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region.
Study: NCT04564690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)
Description: Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular hen eggs
Description: Consumption of three regular hen eggs per day for three weeks
Study: NCT02014506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 4 and continuing until blood counts recover

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCRαβ-depleted hematopoietic cell transplantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Immunogenetic depletion of TCRαβ cells
Study: NCT00711594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2 40mg/day
Description: Phase I step: Increased dose cohorts from low dose to MTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2 50mg/day
Description: Phase I step: Increased dose cohorts from low dose to MTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 MA2 20mg/day
Description: Phase I step: Increased dose cohorts from low dose to MTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 QD
Description: Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
Study: NCT01708148

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control group would receive a oral lactose placebo
Study: NCT03816852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hucMSCs
Description: Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hucMSCs
Description: Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hucMSCs
Description: Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
Study: NCT02554565

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor biopsy
Description: Tumor biopsy before treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sample before, during and after treatment
Study: NCT03083080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30 mL 0.5% ropivacaine is used to achieve VATS block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
Study: NCT03795038

Intervention type: DEVICE
Group type: OTHER
Intervention: Lipoprotein Apheresis MONET and DALI
Description: Three apheresis treatments assigned to one type of apheresis system of MONETand DALI

Intervention type: DEVICE
Group type: OTHER
Intervention: Lipoprotein Apheresis DIAMED and DALI
Description: Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
Study: NCT04437459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat shake
Description: Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pure glucose solution
Description: Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.
Study: NCT04495036

Intervention type: OTHER
Intervention: data collection (21-items-patient descriptive survey)
Description: Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:~* Demographic data of telemedicine users and non-users~* Subjective disease perception of the dermatology patients~* Use of internet, telemedicine and telemedicine insurance model~* Patients´ willingness for additional features of telemedicine~* Advantages and disadvantages telemedicine and face-to-face consultation~* Suitable fields of dermatology for telemedicine from the patient's perspective~* Recommended structure of telemedical services by users and non-users

Intervention type: OTHER
Intervention: data collection (23-items-physician descriptive survey)
Description: To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:~* Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)~* Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective
Study: NCT02455037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Strengthening
Description: Targeted neck strengthening exercises
Study: NCT01404923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti spasmodic agents
Description: best standard of care prescriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alverine citrate, simeticone
Description: on-demand therapy
Study: NCT04460482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near-infrared spectroscopy (NIRS)
Description: NIRS-guided PCI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Angiography guided PCI
Study: NCT00911027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound guided biopsy
Description: One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound guided systematic biopsy
Description: Current practice of ultrasound guided systematic biopsy
Study: NCT01833819

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine and lidocaine

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Study: NCT02777073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Victoza
Description: Single dose of Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of generic placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: single dose of 10 mg dapagliflozin
Study: NCT00764322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Genetic analysis of blood sample.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: gene expression analysis
Description: Genetic analysis of blood sample.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Genetic analysis of blood sample.
Study: NCT02733939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home monitoring kit
Description: The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~* leaves the home without notice, since this might occur in a moment of disorientation;~* leaves a water tap open;~* forgets something on the stove;~* gets out of bed during the night and doesn't come back within a certain time interval;~* never goes to the bathroom in 24 hours;~* never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~* automatically turn on a light to help avoid a fall during the night;~* alert the caregiver when the temperature in the house falls or rises excessively;~* act as burglar alarm in some areas of the home.
Study: NCT04748120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative management
Description: Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
Study: NCT00764322

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacogenomic studies
Description: Genetic analysis of blood sample.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
Study: NCT03741140

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motivation tests
Description: Motivation tests will characterize elementary deficits of motivation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motivation tests
Description: Motivation tests will characterize elementary deficits of motivation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motivation tests
Description: Motivation tests will characterize elementary deficits of motivation
Study: NCT04583267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration
Description: Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
Study: NCT04317898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus plane block by ultra-sound
Description: To perform Serratus block, patients will be placed in the lateral decubitus position with the affected side facing up, or in the prone position with the affected side facing the operator . After sterile preparation, a linear ultrasound probe will be utilized to identify the latissimusdorsi and serratus anterior muscles in a sagittal plane. The plane superficial to the serratus anterior muscle and below the latissimusdorsi muscle will be identified. The skin will be topicalized with 1 mL of 1% lidocaine using a 30-gauge needle. Using an in-plane approach, a 25-gauge 1.5-cm needle will be used to inject a total of 20-mL of 0.25% bupivacaine with 80 mg of triamcinlone under direct ultrasound visualization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block by ultra-sound
Description: TPVB will be given using high frequency linear US transducer, place the probe parallel to the vertebral spine at T2 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of plura, transverse process and paravertebral space, the needle will be inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 10ml of 0.25% bubivacine and 80mg triamcinlone slowly; the pleura will be seen to be pushed downward.
Study: NCT02611934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild Therapeutic Hypothermia (MHT)
Description: The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
Study: NCT04748120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative management
Description: Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~* piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~* amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~* ertapenem 1g IV every 24 hours for 3 days~* ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis.